Sethuraman Natarajan sold TRDA

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001873394-26-000003

Machine-readable

Structured copy

Timestamps

Event (reported)

May 4, 2026

Published

May 4, 2026

Ingested by INSIDER

Nov 5, 04:01 UTC

Last re-read

Nov 5, 04:01 UTC

Extracted facts

Filer

Sethuraman Natarajan

Role

President, Research & Develop.

Transaction

Open-market saleAs filed: “S”

Asset

Entrada Therapeutics, Inc.

Ticker

TRDA

Shares

25.9K

Price per share

$15.39

Value

$398,810

Execution date (reported)

May 4, 2026

Owned after transaction

216.3K shares

Rule 10b5-1 plan

Yes, as checked by the filer

Days from execution to publication

0

Calculation

What this establishes

Sethuraman Natarajan filed this Form 4 reporting a open-market sale of TRDA on May 4, 2026. It became public on May 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

President, Research & Develop.

Sethuraman Natarajancik:0001873394

Issuer

Entrada Therapeutics, Inc.cik:0001689375

Revision history · 0

No field has changed since this record was first ingested.